➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Express Scripts
Dow
McKinsey
McKesson

Last Updated: August 4, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,220,747

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,220,747 protect, and when does it expire?

Patent 9,220,747 protects NOCDURNA and is included in one NDA.

This patent has forty-two patent family members in twenty-eight countries.

Summary for Patent: 9,220,747
Title:Methods using desmopressin acetate in orodispersible form
Abstract: Described are orodispersible solid dosage forms of desmopressin or a pharmaceutically acceptable salt thereof useful for treating diseases or conditions such as incontinence, primary nocturnal enuresis (PNE), nocturia, and central diabetes insipidus. The dosage forms disintegrate in the mouth within 10 seconds and provide good desmopressin bioavailability.
Inventor(s): Nilsson; Anders (Lund, SE), Lindner; Hans (Berlin, DE), Wittendorff; Jcrgen (Hvidovre, DK)
Assignee: FERRING B.V. (Hoofddorp, NL)
Application Number:14/326,939
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,220,747
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 9,220,747

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-001 Jun 21, 2018 RX Yes No   Start Trial   Start Trial TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS   Start Trial
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-002 Jun 21, 2018 RX Yes Yes   Start Trial   Start Trial TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,220,747

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0210397.6May 7, 2002
PCT/IB02/04036Sep 20, 2002

International Family Members for US Patent 9,220,747

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 039092   Start Trial
Argentina 039794   Start Trial
Argentina 107948   Start Trial
Austria 333886   Start Trial
Australia 2002337419   Start Trial
Australia 2003233118   Start Trial
Australia 2003299480   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Express Scripts
Dow
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.